Ultragenyx Pharmaceutical Stock News

NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)s stock price was down 3.4% during trading on Wednesday . The company traded as low as $84.91 and last traded at $84.91. Approximately 8,381 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 480,846 shares. The stock had previously closed at $87.86. A number []

Wall Street brokerages predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will report earnings of ($1.50) per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Ultragenyx Pharmaceuticals earnings, with estimates ranging from ($3.32) to ($0.76). Ultragenyx Pharmaceutical posted earnings of ($1.34) per share in the same quarter last year, which []

EFG Asset Management Americas Corp. acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the third quarter, Holdings Channel reports. The firm acquired 2,979 shares of the biopharmaceutical companys stock, valued at approximately $269,000. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes []

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average recommendation of Buy from the eighteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month []

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given an average rating of Buy by the eighteen brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average []

Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.

NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the first patient has been dosed in its Phase 1/2 study of UX053, an investigational messenger RNA (mRNA) therapy in development for the treatment of Glycogen Storage Disease Type III (GSDIII).

NOVATO, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the Evercore ISI 4th Annual HealthconX Conference on December 1, 2021 at 12:10 PM ET.

NOVATO, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 0.75% to the previous days close as strong demand from buyers drove the stock to $77.58. Actively observing the price movement in the last trading, the stock closed the session at $77.00, falling within a range of $75.135 Read This First Before You Buy Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stock Read More »

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) hit a new 52-week low during trading on Wednesday . The company traded as low as $74.11 and last traded at $77.00, with a volume of 480089 shares changing hands. The stock had previously closed at $77.62. A number of analysts have recently commented on the stock. SVB Leerink []

Royal Bank of Canada boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 401.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,006 shares of the biopharmaceutical companys stock after purchasing an additional 25,627 shares during the period. Royal Bank of []

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)s traded shares stood at 0.31 million during the last session, with the companys beta value hitting 1.64. At the close of trading, the stocks price was $79.32, to imply an increase of 2.49% or $1.93 in intraday trading. The RARE shares 52-week high remains $179.65, putting it -126.49% down since that Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)s -1.50-Percent Loss Of This Past Week Taught Us Something New Read More »